ArticleIJTLD open2025
New drugs are not enough: addressing social determinants as a critical component of drug-resistant TB care.
Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The global fight against drug-resistant TB (DR-TB) is hindered by an underappreciation of the importance of the social determinants of TB. Although shorter, all-oral regimens have improved treatment options, high rates of non-adherence persist due to stigma, financial hardship and other healthcare access barriers. Lessons from HIV highlight the importance of addressing structural and psychosocial factors in treatment management. Consideration of an ecosocial framework integrating biological, social and environmental perspectives is critical for effective DR-TB interventions. A paradigm shift toward patient-centered care and social support strategies is urgently needed to improve treatment outcomes and advance global efforts to eradicate DR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.